MARKET

IMMU

IMMU

Immunomedics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.67
-0.06
-0.29%
After Hours: 20.67 0 0.00% 17:00 12/13 EST
OPEN
20.70
PREV CLOSE
20.73
HIGH
21.37
LOW
20.62
VOLUME
1.62M
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
11.55
MARKET CAP
4.31B
P/E (TTM)
-13.6960
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of IMMU and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

IMMU News

  • Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
  • Zacks.1d ago
  • The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win
  • Benzinga.1d ago
  • Daily Insider Ratings Round Up 12/9/19
  • Seeking Alpha - Article.1d ago
  • The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint
  • Benzinga.2d ago

More

Industry

Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
+0.01%

Hot Stocks

Name
Price
%Change

About IMMU

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.
More

Webull offers Immunomedics, Inc. (IMMU) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.